SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Genzyme Tissue Repair - GZTR -- Ignore unavailable to you. Want to Upgrade?


To: BWAC who wrote (217)7/21/1999 3:14:00 PM
From: Steven C. Vartan  Read Replies (1) | Respond to of 405
 
GENZ can buy back GZTR for a 30% premium to the market which would lock in a big loss to me and all the others who bought at the last secondary at $7.75. Once the company is making a profit the repurchase of shares acts as a reverse dilution and increases the EPS. For mama to buy the orphan at distressed prices would invite lawsuits. Getting profitable then buying back some shares does make lots of sense.